Lecanemab for Alzheimer’s disease

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

(2022) Amir Abbas Tahami Monfared et al.   Neurology and Therapy

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

(2021) Sarah F Ackley et al.   BMJ-British Medical Journal

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease

(2021) Edo Richard et al.   Alzheimers & Dementia

Aducanumab for Alzheimer’s disease?

(2021) Sebastian Walsh et al.   BMJ-British Medical Journal

Clinical effectiveness of the START (STrAtegies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial

(2019) Gill Livingston et al.   BRITISH JOURNAL OF PSYCHIATRY

Person-specific contribution of neuropathologies to cognitive loss in old age

(2018) Patricia A. Boyle et al.   ANNALS OF NEUROLOGY

Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1)

(2018) Andreas Charidimou et al.   International Journal of Stroke

Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial

(2013) G. Livingston et al.   BMJ-British Medical Journal

Epidemiological Pathology of Dementia: Attributable-Risks at Death in the Medical Research Council Cognitive Function and Ageing Study

(2009) Fiona E. Matthews et al.   PLOS MEDICINE